Related Experiment Video
Updated: Aug 26, 2026
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
Amyloid-beta(25-35)-induced memory impairments correlate with cell loss in rat hippocampus
Mikhail Yu Stepanichev1, Irina M Zdobnova, Irina I Zarubenko
1Department of Functional Biochemistry of the Nervous System, Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 5a Butlerov Str., Moscow 117485, Russia.
Abstract:
Amyloid beta-peptide (Abeta) plays an important role in the pathophysiology of Alzheimer's disease. The relationship between amnesia induced by central administration of aggregated Abeta(25-35) and neurodegeneration in the hippocampus was investigated. One month after a single intracerebroventricular injection of Abeta(25-35) (15 nmol), male Wistar rats were tested in an eight-arm radial maze. A quantitative evaluation of cell number in hippocampal regions was carried out on H&E-stained brain sections of rats used in the behavioral study. Indices of free radical-mediated processes in the hippocampus were evaluated in additional groups of animals 1, 3, 5, and 30 days after surgery. Abeta(25-35) induced impairments of working and reference memory (RM) as well as neurodegeneration in the CA1 but not in the CA3 field of the hippocampus. A significant correlation between both reference and working memory (WM) impairments and the neuronal cell loss in the hippocampal CA1 region was demonstrated. A gradually developing oxidative stress was evident in the hippocampus of rats treated with Abeta(25-35) as indicated by the increase in 2-thiobarbituric acid (TBARS) reactive substances and superoxide generation. These data suggest the involvement of oxidative stress in Abeta(25-35)-induced neurodegeneration and a relation between memory impairment and neurodegeneration in the CA1 subfield of the hippocampus.
Insights
Amyloid beta-peptide (Abeta) injection caused memory loss and CA1 hippocampus damage in rats. Oxidative stress appears to drive this Abeta-induced neurodegeneration and memory impairment.
Area of Science:
- Neuroscience
- Pathophysiology
- Alzheimer's Disease Research
Background:
- Amyloid beta-peptide (Abeta) is implicated in Alzheimer's disease pathogenesis.
- Investigating the link between Abeta-induced amnesia and hippocampal neurodegeneration is crucial.
Purpose of the Study:
- To examine the relationship between aggregated Abeta(25-35) administration and memory deficits.
- To assess neurodegeneration in the hippocampus following Abeta(25-35) exposure.
- To explore the role of oxidative stress in Abeta-induced neuronal damage.
Main Methods:
- Intracerebroventricular injection of aggregated Abeta(25-35) in male Wistar rats.
- Behavioral testing using an eight-arm radial maze to assess memory.
- Histological analysis (H&E staining) for quantitative cell counting in hippocampal regions.
- Biochemical assays to measure oxidative stress markers (TBARS, superoxide generation) in the hippocampus.
Main Results:
- Abeta(25-35) induced significant impairments in working memory (WM) and reference memory (RM).
- Neurodegeneration was observed in the CA1 subfield, but not the CA3 field, of the hippocampus.
- A strong correlation was found between memory deficits and neuronal cell loss in the CA1 region.
- Gradual development of oxidative stress, indicated by increased TBARS and superoxide generation, was evident in the hippocampus.
Conclusions:
- Abeta(25-35) administration leads to both memory impairment and neurodegeneration in the rat hippocampus.
- Oxidative stress is involved in the mechanism of Abeta(25-35)-induced neurodegeneration.
- The findings highlight a connection between CA1 hippocampal neurodegeneration and memory dysfunction in an Alzheimer's disease model.
